Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study
Introduction: Regorafenib and TAS-102 are two orally-administered drugs used to treat refractory metastatic colorectal cancer (mCRC). This study was performed to explore any differences between different therapy sequences: TAS-102 first or regorafenib first. Patients and methods: This is a retrospec...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/2/596 |